News
Kamada signs distribution agreement for Alpha-1 infusion product
Israeli drug development company Kamada Ltd. has signed a distribution agreement in the US worth a minimum of $15 million for the company’s Alpha-1 Antitrypsin (AAT) protein for the treatment of congenital emphysema.
The agreement applies only to the injectable version of the drug, while Kamada has reserved distribution rights to the inhalable version.
The five-year distribution agreement is “with a large US company,” whose identity Kamada did not disclose.
Kamada’s injectable AAT has already passed its Phase III clinical trial, and the agreement will come into effect when the US Food and Drug Administration (FDA) gives the drug marketing clearance.
The company expects approval in the second half of 2010.
